Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study
View ORCID ProfileCatherine S. Storm, Demis A. Kia, Mona Almramhi, Dilan Athauda, International Parkinson’s Disease Genomics Consortium (IPDGC), Stephen Burgess, Thomas Foltynie, Nicholas W. Wood
doi: https://doi.org/10.1101/2020.10.20.20215855
Catherine S. Storm
1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom
Demis A. Kia
1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom
Mona Almramhi
1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom
2Department of Medical Laboratory Technology, King Abdulaziz University, Jeddah, Saudi Arabia
Dilan Athauda
1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom
Stephen Burgess
3MRC Biostatistics Unit, University of Cambridge, United Kingdom
4Cardiovascular Epidemiology Unit, University of Cambridge, United Kingdom
Thomas Foltynie
1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom
Nicholas W. Wood
1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom
Data Availability
The GWAS data used by this study are publicly available as stated in the original publications. The supplementary information contains full results. We make our code openly available at https://github.com/catherinestorm/mr_exenatide.
Posted October 21, 2020.
Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study
Catherine S. Storm, Demis A. Kia, Mona Almramhi, Dilan Athauda, International Parkinson’s Disease Genomics Consortium (IPDGC), Stephen Burgess, Thomas Foltynie, Nicholas W. Wood
medRxiv 2020.10.20.20215855; doi: https://doi.org/10.1101/2020.10.20.20215855
Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study
Catherine S. Storm, Demis A. Kia, Mona Almramhi, Dilan Athauda, International Parkinson’s Disease Genomics Consortium (IPDGC), Stephen Burgess, Thomas Foltynie, Nicholas W. Wood
medRxiv 2020.10.20.20215855; doi: https://doi.org/10.1101/2020.10.20.20215855
Subject Area
Subject Areas
- Addiction Medicine (399)
- Allergy and Immunology (710)
- Anesthesia (201)
- Cardiovascular Medicine (2950)
- Dermatology (250)
- Emergency Medicine (440)
- Epidemiology (12755)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4590)
- Geriatric Medicine (419)
- Health Economics (729)
- Health Informatics (2921)
- Health Policy (1069)
- Hematology (389)
- HIV/AIDS (925)
- Medical Education (426)
- Medical Ethics (115)
- Nephrology (469)
- Neurology (4366)
- Nursing (236)
- Nutrition (640)
- Oncology (2273)
- Ophthalmology (647)
- Orthopedics (258)
- Otolaryngology (325)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (501)
- Pediatrics (1197)
- Primary Care Research (497)
- Public and Global Health (6948)
- Radiology and Imaging (1530)
- Respiratory Medicine (915)
- Rheumatology (438)
- Sports Medicine (385)
- Surgery (489)
- Toxicology (60)
- Transplantation (212)
- Urology (181)